Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DTC ads

This article was originally published in The Tan Sheet

Executive Summary

Three OTC analgesics - Bayer aspirin, McNeil's Tylenol and Whitehall-Robins' Advil - placed in the top ten for best-remembered drug ad campaigns among 4,485 consumers surveyed by Scott-Levin. The most recalled ads were for Pfizer's Viagra erectile dysfunction treatment, followed by Schering-Plough's Claritin. Claritin and other non- and low-sedating antihistamines have been cited as a Rx-to-OTC switch candidates (1"The Tan Sheet" July 3, p. 3). Schering spent $34.1 mil. on Claritin DTC ads from January to April, a 37.7% decline from a year ago

You may also be interested in...



Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA

Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel